Shares of Argenx SE (ARGX) surged 5.33% in intraday trading following the release of its second-quarter financial results, which handily exceeded analyst expectations on both the top and bottom lines.

The biotech company reported quarterly adjusted earnings of $7.32 per share, crushing the consensus estimate of $6.24 per share — a beat of over 17%. Revenue for the quarter came in at $1.542 billion, also surpassing the projected $1.442 billion. Compared to the same period last year, earnings nearly doubled from $3.74 per share, while sales soared by 59.43%, underscoring the growing commercial strength of the company's product portfolio.

The robust quarterly performance has ignited bullish sentiment among investors, with the stock initially rallying over 5% in the pre-market session and sustaining those gains into the regular trading day. Wall Street analysts maintain a strong buy consensus on the stock, with a median 12-month price target reflecting further upside potential.